Last reviewed · How we verify
GSK1521498
GSK1521498 is a small molecule drug that targets the S1P1 receptor.
GSK1521498 is a small molecule drug that targets the S1P1 receptor. Used for Multiple sclerosis.
At a glance
| Generic name | GSK1521498 |
|---|---|
| Sponsor | GlaxoSmithKline |
| Drug class | S1P receptor modulator |
| Target | S1P1 |
| Modality | Small molecule |
| Therapeutic area | Autoimmune diseases |
| Phase | Phase 2 |
Mechanism of action
S1P1 is a sphingosine-1-phosphate receptor that plays a role in lymphocyte trafficking and immune response. By targeting this receptor, GSK1521498 aims to modulate the immune system and potentially treat autoimmune diseases.
Approved indications
- Multiple sclerosis
Common side effects
- Headache
- Nausea
- Diarrhea
Key clinical trials
- GSK1521498 Alcohol Interaction Study (PHASE1)
- A First-Time-In-Human Study in Healthy Subjects (PHASE1)
- [11C]Carfentanil PET Study of GSK1521498 (PHASE1)
- Effects of Repeat Dosing of GSK1521498 (PHASE1)
- To Evaluate the Influence of the A118G Polymorphism in the mu Opioid Receptor Gene (OPRM1) on Effects of GSK1521498 and Naltrexone on Physiological and Behavioural Markers of Brain Function in Healthy Social Drinkers (PHASE1)
- A 35 Day Study to Investigate the Effects of GSK1521498 on Bodyweight in Obese Subjects With Over-Eating Behaviours. (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |